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Glucocorticoid Sensitivity of Circulating
Monocytes in Essential Hypertension
Petra H. Wirtz, Roland von Ka¨nel, Karl Frey,
Ulrike Ehlert, and Joachim E. Fischer
Background: Essential hypertension ranks among the
strongest cardiovascular risk factors. Cytokine production
by monocytes plays a key role in atherosclerosis develop-
ment and acute coronary syndromes. We investigated
whether stimulated monocyte cytokine release and its in-
hibition by glucocorticoids would differ between hyper-
tensive and normotensive subjects.
Methods: Study participants were 222 middle-aged male
employees with industrial jobs. Following the criteria of the
World Health Organization/International Society for Hyper-
tension, 76 subjects were classified as being hypertensive
(systolic blood pressure 140 mm Hg or diastolic blood
pressure 90 mm Hg). In vitro monocyte tumor necrosis
factor (TNF)- release after lipopolysaccharide (LPS) stim-
ulation was assessed with and without coincubation with
incremental doses of dexamethasone. Monocyte glucocorti-
coid sensitivity was defined as the dexamethasone concen-
tration inhibiting TNF- release by 50%.
Results: Hypertensive subjects showed 11% higher
LPS-stimulated TNF- release than normotensive subjects
(F1,181 5.21 , P .024). In hypertensive subjects, mono-
cyte glucocorticoid sensitivity was 21% lower than in
normotensive subjects (F1,178 4.94, P .027), indicating
that dexamethasone inhibited relatively less TNF- re-
lease in hypertensive subjects. Results held significance
when a set of classic cardiovascular risk factors was con-
trolled for.
Conclusion: The findings suggest that proinflamma-
tory activity of circulating monocytes is higher in hyper-
tensive than in normotensive men, providing one potential
pathway to explain the increased atherosclerotic risk with
essential hypertension. Am J Hypertens 2004;17:
489–494 © 2004 American Journal of Hypertension, Ltd.
Key Words: Essential hypertension, glucocorticoid
sensitivity, monocytes, cytokines, cardiovascular disease.
P rimary hypertension ranks among the leading riskfactors for vascular diseases.1,2 The mechanismsthat link hypertension with increased incidence of
atherosclerosis are not fully understood.3,4 Monocytes
play a key role in the pathogenesis and progression of
atherosclerosis.5,6 They secrete inflammatory cytokines
that further promote inflammation in atherosclerotic le-
sions.5–8 Elevated plasma levels of proinflammatory cy-
tokines such as tumor necrosis factor (TNF)- or
interleukin (IL)-6 have been prospectively associated with
increased cardiovascular risk in healthy individuals and in
those with coronary artery disease.9–11 Although this has
not been investigated prospectively, exaggerated mono-
cyte proinflammatory cytokine release might account for
heightened cardiovascular risk in hypertension.
Regulatory processes in monocyte cytokine release en-
tail stimulation of cytokine secretion as well as its inhibi-
tion. A potent stimulator of monocyte cytokine production
is lipopolysaccharide (LPS), whereas glucocorticoids ef-
fectively down-regulate monocyte cytokine release.12–14
In a previous study LPS-stimulated monocyte cytokine
release has been examined in 22 hypertensive patients. In
that study, peripheral blood monocytes of patients with
essential hypertension secreted more TNF- and IL-1
but not more IL-6 in response to LPS than did monocytes
from normotensive control subjects.15 As a whole, there is
a paucity of investigation concerning regulation of human
monocyte activity in essential hypertension.15 Moreover,
despite the fact that excess cortisol is known to elevate
blood pressure (BP),16 to the best of our knowledge,
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down-regulation of monocyte cytokine release by glu-
cocorticoids has not been investigated in hypertensive
subjects.
We thus wondered whether suppression of the mono-
cyte proinflammatory response by glucocorticoids (ie,
monocyte glucocorticoid sensitivity) would be altered in
hypertensive compared with normotensive individuals.
Such a difference might provide one biologic mechanism
linking hypertension with the pathogenesis of atheroscle-
rosis. Following previous methods, we assessed monocyte
reactivity by means of measuring TNF- in whole blood
after LPS stimulation.13,14 We calculated the monocyte
glucocorticoid sensitivity as the concentration of dexa-
methasone required to suppress LPS-stimulated TNF-
release by 50%.12,17,18
Methods
Study Population
The Institutional Review Board of the Swiss Federal In-
stitute of Technology approved the study protocol and the
process for obtaining informed consent. A representative
sample of 647 men and women from a total of 1760
employees of an airplane manufacturing plant in Southern
Germany were invited to participate in the study. Of these,
325 subjects (280 men and 45 women) volunteered to
participate. Except for a slightly higher age, there were no
baseline demographic differences between volunteers and
nonparticipants (data not shown). For the present study,
we considered only men to avoid hormonal confounding
of inflammatory activity by oral contraceptives or by the
female cycle. We excluded subjects who were on any
antihypertensive medication (including -blockers), hor-
mone therapy, psychoactive drugs, or steroids. This pro-
cedure left 222 men, all of white ethnicity, whom we
classified into hypertensive and normotensive individuals
based on their BP following the World Health Organiza-
tion/International Society for Hypertension definition (sys-
tolic BP 140 mm Hg or diastolic BP 90 mm Hg).19 In
the following sections, we present the comparisons be-
tween hypertensive (n  76) and normotensive (n  146)
men. Table 1 lists characteristics of the study participants.
Experimental Protocol
All subjects completed an extensive questionnaire with
respect to personal medical history, cardiovascular risk
factors, intake of medications, and medical history of the
participants’ mother and father as previously de-
scribed.20,21 None of the individuals with hypertension
were on any medication to reduce BP, and only two of the
hypertensive subjects were aware of their condition.
Thereafter, subjects had a 15-min rest period while sitting,
followed by BP determination twice within 5 min using a
mercury sphygmomanometer. All subjects also had their
weight and height measured to compute the body mass
index (BMI).
Within 3 weeks, all participants were rescheduled on a
workday and 2 h after awakening (between 7:00 AM and
8:45 AM) for collection of a fasting blood sample. Assays
were started within 5 min from blood collection in a cell
culture facility adjacent to the blood collection room. For
the TNF- assay, blood was processed by standard tech-
niques using cooled (4°C) citrated tubes. Urine collection
for overnight cortisol secretion started at 9:00 PM the night
before blood sampling, ending with the inclusion of the
first void after awakening.22
Glucocorticoid Sensitivity and Assay
Monocytes are the main cytokine producing cells in LPS-
stimulated whole blood.23 To assess glucocorticoid sensi-
tivity of stimulated cytokine production, dexamethasone
has been widely used.12,14,24 Because of its association
with atherosclerosis,5,25 we chose to study TNF- plasma
concentrations. TNF- plays a crucial role in the initial
activation of inflammatory changes such as stimulation of
C-reactive protein production by the liver, which is
thought to sustain atherosclerosis development.6
The whole blood cell culture is an in vitro method to
analyze cytokine secretion in a controlled environment as
Table 1. Health factors of normotensive and hypertensive men
Normotensive
(n  146)
Hypertensive
(n  76) P
Systolic BP (mm Hg) 124  0.67 146  1.8  .001
Diastolic BP (mm Hg) 77.1  0.5 92.0  1.2  .001
Age (y) 37.9  0.7 45.2  0.9  .001
Body mass index (kg/m2) 25.66  0.2 27.5  0.4  .001
LDL/HDL ratio 2.89  0.08 3.18  0.11 .032
Hemoglobin Alc (%) 5.11  0.03 5.28  0.05 .005
Cigarettes/day 6.6  0.8 5.2  1.2 .331
Unstimulated TNF- (pg/mL) 1.92  0.15 1.88  0.08 .853
Monocytes (105/mL) 5.95  0.14 5.83  0.18 .605
Urinary cortisol (g/L) 41.9  2.1 46.9  5.4 .306
Values given are mean  SEM.
BP  blood pressure; HDL  high-density lipoprotein cholesterol; LDL  low-density lipoprotein cholesterol.
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well as to study the biologic effects of drugs on cytokine
release 26,27 The whole blood assay avoids possible biases
through artificial stimulation of monocytes arising from
preanalytical steps by mononuclear cell separation, and it
also preserves the “natural environment” (including hor-
mones) of cytokine producing cells.27,28
The basic principle of the glucocorticoid sensitivity
assay is to use a stimulant for cytokine release coincubated
with particular concentrations of a glucocorticoid. After a
defined incubation period, the cytokine content of the
supernatant is determined. If a stimulant such as LPS is
used that predominantly activates monocytes, and if a
cytokine such as TNF- is assessed whose main source in
LPS-stimulated whole blood is monocytes, one may be
confident that the assay mainly reflects monocyte regula-
tion.
The assay provides two major endpoints: a) the cyto-
kine release in response to LPS (without glucocorticoid
costimulation), and b) the estimated glucocorticoid con-
centration that would exactly inhibit 50% of the LPS-
stimulated cytokine release determined from (a). Measure
(b) is independent from the absolute cytokine release, and
it has been referred to as the IC50, which is a single-
measure index to describe the glucocorticoid sensitivity.
To estimate IC50 values from the inhibition curve, we used
a logistic function.
In detail, the method was as follows. Venous blood was
collected in heparinized tubes, diluted 1:10 with saline.
The blood was then incubated with LPS (Escherichia coli,
055:B5, no. L2880; Sigma-Aldrich Chemie GmbH, Stein-
heim, Germany) and five different concentrations of dexa-
methasone (no. D8893, Sigma-Aldrich Chemie), both
dissolved in sterile saline solution (NaCl 0.9%, Fresenius
Kabi, Stans, Switzerland), on a 24-well plate (no. 3047;
Becton Dickinson, San Diego, CA). Diluted whole blood
(400 L) was added to 50 L of LPS and to 50 L of
various concentrations of dexamethasone. Final concen-
trations on the plate were 15 ng/mL LPS and 0, 1010,
109, 108, and 107 mol/L dexamethasone. After a 6-h
incubation period at 37°C in 5% CO2, plates were centri-
fuged for 10 min at 2000 g at 4°C.12,14 The supernatant
was collected and stored at 80°C until assayed.
Biochemical Analyses
In vitro levels of TNF- were determined using commer-
cial ELISA kits (BD Pharmingen, San Diego, CA). A
high-sensitivity assay was chosen to measure in vivo
plasma levels of TNF- (ELISA; Quantikine HS, R&D
Systems Europe, Abington, UK). Low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) choles-
terol, hemoglobin A1c (HbA1c), and urinary cortisol were
determined by a commercial laboratory (Synlab, Augs-
burg, Germany) by means of standard procedures. Mono-
cyte counts were determined from EDTA samples within
3 h from blood sampling using the SE-9000 cell counter
(Sysmex, Norderstedt, Germany).
Statistical Analyses
All calculations were performed using SPSS version 10.0
(SPSS, Chicago, IL) and Curve Expert version 1.3 soft-
ware packages (Shareware, Daniel Hyams, Starkville,
MS). Data are presented as mean  SEM. Results were
considered statistically significant at the level of P  .05,
and all tests were two-tailed. In case of missing data, cases
were excluded listwise. Across the two subject groups,
univariate analyses of variance (ANOVAs) were calcu-
lated for health factors (Table 1). Univariate analyses of
covariance were computed for LPS-stimulated cytokine
production, and IC50 values with the following established
cardiovascular risk factors as covariates: age, BMI,
HbA1c, LDL/HDL ratio, systolic BP, diastolic BP, and the
number of cigarettes smoked per day. The rationale for
including these parameters in statistical analyses was to
assess group differences independently of other estab-
lished cardiovascular risk factors aside from hypertension.
Because monocytes are the main source of cytokine pro-
duction upon stimulation with LPS, whole blood cytokine
production was corrected for the monocyte count.12 In
contrast, we did not correct basal TNF- levels for mono-
cyte count, as basal TNF- levels likely originate from
different kinds of cells and not only from circulating
monocytes.
Results
Cardiovascular Risk Factors
and Health Factors
Table 1 shows that hypertensive subjects were older and
that they had higher BMI, HbA1c, and LDL/HDL ratio
than normotensive subjects. Parents of subjects with hy-
pertension had more often experienced cardiovascular
events (number of myocardial infarctions and strokes
combined) than parents of subjects with normal BP (odds
ratio [OR]  2.0, 95% confidence interval [CI]  1.1 to
3.8, P  .028). To ascertain that this effect was not
confounded by the age of the study participants, we con-
ducted multivariable logistic regression analysis on the
most prominent effect, the difference in reporting that the
participant’s mother had experienced a stroke. After con-
trolling for the participants’ age, individuals with high BP
at examination reported significantly more often that their
mother had experienced stroke than individuals with nor-
mal BP (adjusted OR  7.5, 95% CI  1.4 to 40, P 
.018).
In subsequent analyses, we controlled for all cardiovas-
cular risk factors to rule out their influences on the ob-
served dependent variables. Of note, TNF- was not
different between normotensive and hypertensive individ-
uals, and neither was there a significant correlation be-
tween systolic BP (r  0.01, P  .91) and diastolic BP
(r  0.04, P  .59) with basal TNF- in vivo. We found
similar overnight urinary cortisol excretion in hyperten-
sive and normotensive individuals, which may indicate
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that subjects with differential LPS stimulation of TNF-
had equal activity of the hypothalamus–pituitary–adrenal
axis.
Stimulation of Cytokine Production
There was no significant association of systolic BP (r 
0.04, P  .60) or of diastolic BP (r  0.02, P  .82)
with change scores of TNF- from baseline to LPS stim-
ulation. After the absolute monocyte count and previously
mentioned cardiovascular risk factors were taken into ac-
count, hypertensive subjects showed higher LPS-stimu-
lated TNF- release in vitro than normotensive subjects
(F1,181 5.21 , P  .024; Fig. 1). The absolute difference
was about 11%.
Glucocorticoid Sensitivity
of Cytokine Release
Crude correlation analyses showed positive relationships
between the IC50 and BP that reached significance for
systolic BP (r  0.14, P  .044) but not for diastolic BP
(r  0.11, P  .125). After controlling for the set of
cardiovascular risk factors, hypertensive subjects had
higher IC50 of TNF- than normotensive subjects (F1,178
4.94, P  .027; Fig. 2). The absolute difference was about
21%. In other words, more dexamethasone was required to
suppress TNF- secretion in response to the same amount
of LPS in hypertensive compared with normotensive in-
dividuals. This finding suggests that hypertensive men had
lower monocyte glucocorticoid sensitivity than normoten-
sive men.
Discussion
The main finding of our study is that monocytes of hyper-
tensive men required larger quantities of dexamethasone
to inhibit LPS-stimulated release of TNF- than did
monocytes of normotensive men. In addition, LPS-stimu-
lated TNF- release per cell without glucocorticoid inhi-
bition was significantly higher in subjects with
hypertension. Despite the observation that plasma levels of
unstimulated TNF- were not different between hyperten-
sive and normotensive subjects, our findings suggest
higher pro-inflammatory activity in blood monocytes of
hypertensive men. This possibility is even stronger given
that we controlled for classic cardiovascular risk factors,
which were relatively more prominent in the hypertensive
subjects.
What are the potential clinical implications of these
findings and how do they compare with the literature? Our
results indicate that the proinflammatory response of
monocytes to an equal amount of LPS is higher in hyper-
tensive than in normotensive men. Atherosclerosis is
largely an inflammatory disease5 in which TNF- produc-
tion by monocytes and macrophages plays a central role.29
Although this has not been proved, several lines of evi-
dence point to the possibility that hypertension is a con-
tributor to the inflammatory response of the vessel wall.30
Based on our findings, any LPS-like danger signal (such as
one related to infection or to cellular stress) might elicit
relatively more proinflammatory cytokine production in
hypertensive men, thereby promoting atherosclerosis.
Such reasoning is in line with epidemiologic data support-
ing the notion that elevated plasma levels of TNF- in-
crease the risk of coronary artery disease in nonhyper-
tensive populations.10,11,25 It must be emphasized, how-
ever, that our study was cross-sectional. We thus are
unable to make the distinction whether hypertension
causes an increase in cytokines and thereby atherosclerosis
or whether atherosclerosis as a result, for example, of
increased shear forces to the endothelium causing in-
creased cytokine production. Prospectively designed stud-
ies are necessary to address this important issue.
FIG. 1. Lipopolysaccharide (LPS)–stimulated release of tumor ne-
crosis factor (TNF)- in hypertensive compared with normotensive
men (mean  SEM). Hypertensive men had higher LPS-stimulated
cytokine release than did normotensive men. *P  .024.
FIG. 2. Glucocorticoid sensitivity of lipopolysaccharide (LPS)–stim-
ulated release of tumor necrosis factor (TNF)- between groups.
The IC50 is inversely related to glucocorticoid sensitivity; ie, higher
IC50 indicates lower glucocorticoid sensitivity and vice versa. Hy-
pertensive subjects required relatively more dexamethasone to
suppress LPS-stimulated TNF- secretion than normotensive sub-
jects (*P  .027). In other words, monocytes of hypertensive men
were less sensitive to dexamethasone suppression than monocytes
of normotensive men.
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Our observation corroborates a previous study that
found increased monocyte TNF- and IL-1 release after
LPS stimulation in hypertensive subjects.15 Like our
study, that study was unable to resolve the issue of
whether preactivated monocytes in hypertensive individ-
uals are an epiphenomenon or a causal factor triggering
hypertension or atherosclerosis or both. In another study,
hypertensive persons showed increased IL-1 secretion
after LPS stimulation, whereas TNF- production capacity
of monocytes was decreased.31 The investigators ex-
plained this discrepancy by a differential regulation in the
synthesis of the two cytokines.
To the best of our knowledge, impaired glucocorticoid
sensitivity of LPS-stimulated monocyte cytokine release
in hypertensive individuals has not previously been re-
ported. We offer two possible biologic mechanisms that
might underlie the impaired ability of dexamethasone to
down-regulate LPS-stimulated TNF- release in mono-
cytes of hypertensive persons. First, a population-based
study found that hypertensive men had higher morning
plasma cortisol levels than normotensive men.32 Although
our hypertensive and normotensive subjects had similar
overnight cortisol excretion, we cannot exclude the possi-
bility of intermittent peaks of exaggerated cortisol secre-
tion among hypertensive persons, perhaps resulting in
down-regulation of their glucocorticoid receptors.33,34
Second, cortisol binding to glucocorticoid receptors is
impaired in hypertensive persons,35 rendering a possible
explanation for the observed blunted glucocorticoid sen-
sitivity in our hypertensive subjects.34
Similar to our study, three previous studies found no
differences in unstimulated (ie, basal) plasma TNF- be-
tween hypertensive and normotensive subjects.31,36,37 One
possible explanation for unchanged basal TNF- among
hypertensive and normotensive subjects concurrent with
exaggerated LPS-stimulated TNF- release in hyperten-
sive persons might relate to the stage of the hypertensive
disease. Indeed, one study found slightly increased basal
TNF- only in hypertensive subjects with chronic renal
failure as opposed to subjects having uncomplicated hy-
pertension and normotensive control subjects.37 Unfortu-
nately, we did not assess renal function; we assume,
however, that the vast majority of our middle-aged sub-
jects had not yet developed hypertensive organ damage.
Aside from the cross-sectional nature of our study,
which does not allow us to interpret the direction of the
hypertension–cytokine–atherosclerosis link, three other
limitations need to be addressed. First, our screening pro-
cedure to track subjects with clinical hypertension might
embed a recruitment bias because we measured BP on one
occasion only. Also, our study lacked a systematic assess-
ment of end-organ damage, and the collection of health
variables (including use of antihypertensive medication)
was by subjects’ self-report. Nonetheless, despite this
seemingly unsophisticated BP assessment, hypertensive
subjects reported significantly more often having a parent
who had experienced a major cardiovascular event, for
which hypertension is a strong risk factor, than did sub-
jects who were normotensive. This may suggest that our
categorization of individuals in hypertensive and normo-
tensive subjects was not too simplistic. Second, our inves-
tigation focused on a working male population and our
findings may not be generalizable to women, clinical pop-
ulations, and individuals with overt vascular disease.
Third, the observed differences in monocyte proinflamma-
tory activity between hypertensive and normotensive men
were small. Only the longitudinal follow-up of our cohort,
linking glucocorticoid sensitivity with cardiovascular end-
points, will show whether these differences are of clinical
relevance.
In the meantime, the concept of allostasis and allostatic
load may help to put our findings in a clinical perspective.
Allostasis refers to physiologic adaptation to environmen-
tal challenges, and allostatic load designates health burden
as a consequence of inefficient allostasis.38 Increase in BP
can be understood as an adaptive effort mediated by the
hypothalamus–pituitary–adrenal axis and the sympathetic
nervous system, to meet physiologic demands imposed,
for example, by the work environment.39 Exposure to
hypertension often persists for many years before the
condition is brought to medical attention and treatment.
Numerous accompanying events stimulating monocytes
might, on each occasion, result in a slightly more pro-
nounced inflammatory response. This, in turn, may in-
crease the likelihood that other physiologic processes such
as glucose hemostasis or lipid metabolism may become
deviant from the physiologic equilibrium. Such deviations
across multiple physiologic systems are characteristic for
the early stages of allostatic load, prediciting biologic
morbidity and mortality later on in life.40
In summary, our data suggest that middle-aged hyper-
tensive men show reduced responsiveness of monocytes to
glucocorticoids, implying relatively sustained cytokine
production once monocytes have encountered a stressful
stimulus. Such an exaggerated reactivity of monocytes to
external stimuli and diminished curtailing of monocyte
proinflammatory responses by glucocorticoids might rep-
resent mechanisms linking hypertension with poor cardio-
vascular outcome. The clinical implications of our
observations in health and in cardiovascular disease re-
main to be demonstrated.
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